Beatrice Setnik, PhD, joined Altasciences in August from Syneos Health.
In her new role, Setnik will support early drug development clients as the chief scientific officer. Prior to Syneos, she worked at Pfizer, King Pharmaceuticals, and Ventana Clinical Research.
Setnik also is an adjunct professor in the Department of Pharmacology and Toxicology at the University of Toronto.
“I am grateful to be joining an organization with such passion and dedication to early phase drug development. In my new role, I plan to support the innovation and expertise that Altasciences brings to preclinical and phase I research,” she told us.
“My mission is to continue to drive the science behind what we do and to continuously strive to excel and outperform. In the coming months, I will be reinforcing our center of excellence in CNS research and innovator studies, and helping clients find the optimal strategy for their drug development programs.